Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination.

Langermann S, Palaszynski S, Barnhart M, Auguste G, Pinkner JS, Burlein J, Barren P, Koenig S, Leath S, Jones CH, Hultgren SJ.

Science. 1997 Apr 25;276(5312):607-11.

2.

Adhesins as targets for vaccine development.

Wizemann TM, Adamou JE, Langermann S.

Emerg Infect Dis. 1999 May-Jun;5(3):395-403. Review.

3.

Development of a tripartite vector system for live oral immunization using a gram-negative probiotic carrier.

Buddenborg C, Daudel D, Liebrecht S, Greune L, Humberg V, Schmidt MA.

Int J Med Microbiol. 2008 Jan;298(1-2):105-14. Epub 2007 Oct 23. Review.

PMID:
17936683
4.

[Candidate vaccine against urinary tract infections].

Hoepelman IM, Meiland R, Langermann S.

Ned Tijdschr Geneeskd. 2001 Sep 22;145(38):1860-2. Review. Dutch.

PMID:
11593791
5.

Fimbrial adhesions of Escherichia coli.

Klemm P.

Rev Infect Dis. 1985 May-Jun;7(3):321-40. Review.

PMID:
2862689
6.

[Prospects for the development of an anti-adhesive vaccine against strains of Escherichia coli causing diarrhea in humans (3)].

Cravioto A.

Bol Med Hosp Infant Mex. 1984 May;41(5):253-61. Review. Spanish. No abstract available.

PMID:
6147148
7.

Colonization factor antigens of enterotoxigenic Escherichia coli in animals.

Moon HW.

Curr Top Microbiol Immunol. 1990;151:147-65. Review. No abstract available.

PMID:
1973369
8.

Host-pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection.

Hannan TJ, Totsika M, Mansfield KJ, Moore KH, Schembri MA, Hultgren SJ.

FEMS Microbiol Rev. 2012 May;36(3):616-48. doi: 10.1111/j.1574-6976.2012.00339.x. Review.

9.

Escherichia coli virulence factors.

Mainil J.

Vet Immunol Immunopathol. 2013 Mar 15;152(1-2):2-12. doi: 10.1016/j.vetimm.2012.09.032. Epub 2012 Sep 26. Review.

PMID:
23083938
10.

Tip proteins of pili associated with pyelonephritis: new candidates for vaccine development.

Lund B, Lindberg F, Marklund BI, Normark S.

Vaccine. 1988 Apr;6(2):110-2. Review.

PMID:
2898842
11.

The FimH protein of type 1 fimbriae. An adaptable adhesin.

Klemm P, Schembri M, Hasty DL.

Adv Exp Med Biol. 1996;408:193-5. Review. No abstract available.

PMID:
8895793
12.

Colonization factor antigens of human pathogens.

Evans DJ Jr, Evans DG.

Curr Top Microbiol Immunol. 1990;151:129-45. Review. No abstract available.

PMID:
1973368
13.

Oral vaccines against cholera and enterotoxigenic Escherichia coli diarrhea.

Svennerholm AM, Holmgren J.

Adv Exp Med Biol. 1995;371B:1623-8. Review. No abstract available.

PMID:
7502870
14.

Adhesion and entry of uropathogenic Escherichia coli.

Mulvey MA.

Cell Microbiol. 2002 May;4(5):257-71. Review.

PMID:
12027955
15.

Enterobacterial adhesins and the case for studying SNPs in bacteria.

Weissman SJ, Moseley SL, Dykhuizen DE, Sokurenko EV.

Trends Microbiol. 2003 Mar;11(3):115-7. Review.

PMID:
12648942
16.

In vivo evaluation of FimH antagonists - a novel class of antimicrobials for the treatment of urinary tract infection.

Abgottspon D, Ernst B.

Chimia (Aarau). 2012;66(4):166-9. doi: 10.2533/chimia.2012.166. Review.

PMID:
22613141
17.

Recombinant DNA technology and enterotoxigenic Escherichia coli vaccines.

Gyles CL, Maas WK.

Prog Vet Microbiol Immunol. 1987;3:139-58. Review. No abstract available.

PMID:
3078832
18.

Glycoprotein 2 (GP2): grabbing the FimH bacteria into M cells for mucosal immunity.

Ohno H, Hase K.

Gut Microbes. 2010 Nov-Dec;1(6):407-10. doi: 10.4161/gmic.1.6.14078. Review.

19.

Synthetic peptides: prospects for a pili (fimbriae)-based synthetic vaccine.

Schmidt MA.

Curr Top Microbiol Immunol. 1990;151:185-204. Review. No abstract available.

PMID:
1973370
20.

Supplemental Content

Support Center